Johnson & Johnson - Experiencing Buyer's Remorse

Summary

  • JNJ is teaching investors the importance of valuation.
  • I now realize that JNJ is best purchased closer to the historically low valuation ratios.
  • I overpaid without clearly assessing the risks like the Oklahoma opioid litigation.
  • Investors could get better entry points in this panic environment.

I am long Johnson & Johnson (JNJ) around $142 and I am realizing that I overpaid by at least 10-15 percent. Although I am making short-term trades to reduce my cost-basis and I fully comprehend that in the longer-term I will be able to get out with a decent profit, yet it still does not make up for the fact that I violated a crucial investing lesson. I did my analysis of the company and purchased the shares, but forgot to question myself, is the price right? As I analyze my portfolio now, I realize that I should have purchased it at significantly lower levels.

This analysis is aimed at investors who either made purchases at higher levels or who are thinking about taking fresh positions in J&J. I contend that the investors who have low cost-basis should continue to hold their positions.

READ FULL ARTICLE HERE